Effect of ulinastatin + thymosin adjuvant therapy on inflammatory and stress response in patients with severe pneumonia

摘要

Objective: To investigate the effect of ulinastatin + thymosin adjuvant therapy on inflammatory and stress response in patients with severe pneumonia. Methods: A total of 66 patients with severe pneumonia who were diagnosed and treated in Huanggang Central Hospital between July 2016 and July 2017 were divided into control group (n=33) and study group (n=33) by random number table. Control group received routine therapy for severe pneumonia, and study group received routine therapy combined with ulinastatin + thymosin adjuvant therapy, which lasted for 1 week. The differences in serum levels of inflammatory factors and stress hormones were compared between the two groups before and after treatment. Results: Before treatment, the differences in serum levels of inflammatory factors and stress hormones were not statistically significant between the two groups. After 1 week of treatment, serum levels of inflammatory factors and stress hormones of both groups of patients were lower than those before treatment, serum levels of pro-inflammatory factors IL-1β, IL-2, IL-6, IL-8 and TNF-α as well as anti-inflammatory factors IL-4, IL-10 and IL-13 of study group were lower than those of control group, and serum stress hormones AngⅠ, AngⅡ, NE and Cor levels were lower than those of control group. Conclusion: Routine therapy combined with ulinastatin + thymosin adjuvant therapy can further inhibit the systemic inflammatory response and stress response and optimize the overall condition in patients with severe pneumonia.